The Phase II Study of Panitumumab in Chemotherapy-Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer: OGSG 1602 Final Results

BACKGROUND: We previously reported the response rate of a phase II OGSG1602 study on panitumumab in chemotherapy-naive frail or elderly patients with RAS wild-type unresectable colorectal cancer (CRC) [Terazawa T, Kato T, Goto M, et al. Oncologist. 2021;26(1):17]. Herein, we report a survival analys...

Descripción completa

Detalles Bibliográficos
Autores principales: Terazawa, Tetsuji, Kato, Takeshi, Goto, Masahiro, Ohta, Katsuya, Satake, Hironaga, Noura, Shingo, Kagawa, Yoshinori, Kawakami, Hisato, Hasegawa, Hiroko, Yanagihara, Kazuhiro, Shingai, Tatsushi, Nakata, Ken, Kotaka, Masahito, Hiraki, Masayuki, Konishi, Ken, Nakae, Shiro, Sakai, Daisuke, Kurokawa, Yukinori, Shimokawa, Toshio, Tsujinaka, Toshimasa, Satoh, Taroh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322121/
https://www.ncbi.nlm.nih.gov/pubmed/35947993
http://dx.doi.org/10.1093/oncolo/oyac145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322121/
https://www.ncbi.nlm.nih.gov/pubmed/35947993
http://dx.doi.org/10.1093/oncolo/oyac145

Ejemplares similares